Display Settings:

Items per page

Results: 1 to 20 of 138

1.
Figure 2

Figure 2. From: Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Prior chelation therapy of patients enrolled in the EPIC study included in these analyses.
*One MDS patient in Europe was classified as receiving “other” chelation therapy.

Vip Viprakasit, et al. Blood Transfus. 2013 January;11(1):108-122.
2.
Figure 4

Figure 4. Chelation therapy agents with reported antibacterial activity. From: Targeting iron assimilation to develop new antibacterials.

Ciclopirox 8, deferiprone 9 and deferasirox 10 are three FDA-approved chelation therapy agents that have been investigated for their antifungal activities.

Timothy L. Foley, et al. Expert Opin Drug Discov. ;7(9):831-847.
3.
Figure 1

Figure 1. From: Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.

Iron chelation therapy for patients with thalassemia naïve to iron chelation

Monica Pinheiro de Almeida Veríssimo, et al. Rev Bras Hematol Hemoter. 2013;35(6):428-434.
4.
Figure 3

Figure 3. From: Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.

Iron chelation therapy for patients with thalassemia with cardiac iron overload

Monica Pinheiro de Almeida Veríssimo, et al. Rev Bras Hematol Hemoter. 2013;35(6):428-434.
5.
Figure 2

Figure 2. From: Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.

Iron chelation therapy for patients with thalassemia without cardiac iron overload

Monica Pinheiro de Almeida Veríssimo, et al. Rev Bras Hematol Hemoter. 2013;35(6):428-434.
6.
Figure 3A

Figure 3A. From: Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Mean proportion of lifetime on chelation therapy* for patients enrolled in the EPIC study included in these analyses.
*Determined by the number of years the subject had already received chelation therapy divided by age at screening; regular or intermittent transfusions were not differentiated in the protocol.

Vip Viprakasit, et al. Blood Transfus. 2013 January;11(1):108-122.
7.
Figure 2

Figure 2. From: Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis.

Serum ferritin levels in hematologic responder (HR) and non-responder (NR) patients at the end of iron chelation therapy (ICT).

Elena Maria Elli, et al. Mediterr J Hematol Infect Dis. 2014;6(1):e2014042.
8.
Figure 4

Figure 4. From: Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.

Iron chelation therapy for patients with thalassemia when magnetic resonance imaging is not available

Monica Pinheiro de Almeida Veríssimo, et al. Rev Bras Hematol Hemoter. 2013;35(6):428-434.
9.
FIGURE 1

FIGURE 1. From: Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial.

TACT – Kaplan–Meier estimates of the primary composite endpoint chelation therapy vs. placebo. The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. Reproduced with permission [], previously published in . CI, confidence interval; HR, hazard ratio.

Maria D. Avila, et al. Curr Opin Cardiol. 2014 September;29(5):481-488.
10.
FIGURE 3

FIGURE 3. From: Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial.

TACT – Kaplan–Meier estimates of the primary composite endpoint EDTA chelation therapy vs. placebo subgroup of patients with diabetes mellitus. The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. Reproduced with permission . CI, confidence interval; HR, hazard ratio.

Maria D. Avila, et al. Curr Opin Cardiol. 2014 September;29(5):481-488.
11.
Figure 2

Figure 2. From: Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.

(A) Urinary iron excretion (U- Fe) by deferiprone and deferoxamine. (B) Serum iron (s-Fe), serum ferritin (s- Ferr), haemoglobin (Hb), and mean corpuscular volume (MCV) during iron chelation therapy.

R Mariani, et al. Gut. 2004 May;53(5):756-758.
12.
Figure 4

Figure 4. From: Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients.

TACT Kaplan-Meier Estimates of Death EDTA Chelation Therapy vs. Placebo Subset of Patients with Diabetes: Hx, Med Use or Basefine Glucose>=126
Adapted with permission from
Circulation: Cardiovascular Quality Outcomes:
“Escolar E, Lamas G a, Mark DB, Boineau R, Goertz C, Rosenberg Y, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15–24.”

Julio G. Peguero, et al. Trends Cardiovasc Med. ;24(6):232-240.
13.
Figure 3

Figure 3. From: Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis.

Absolute change in median serum ferritin levels from baseline in hematologic responder (HR) and non-responder (NR) patients at 6, 12, 18 months from start of iron chelation therapy (ICT).

Elena Maria Elli, et al. Mediterr J Hematol Infect Dis. 2014;6(1):e2014042.
14.
Figure 3

Figure 3. From: Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients.

TACT Kaplan-Meier Estimates of the Primary Composite Endpoint EDTA Chelation Therapy vs. Placebo Subset of Patients with Diabetes: Hx, Med Use or Baseline Glucose>=126
Adapted with permission from
Circulation: Cardiovascular Quality Outcomes:
“Escolar E, Lamas G a, Mark DB, Boineau R, Goertz C, Rosenberg Y, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):15–24.”

Julio G. Peguero, et al. Trends Cardiovasc Med. ;24(6):232-240.
15.
Figure 2

Figure 2. From: Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients.

5-year Kaplan-Meier Event Rate Estimates for the Primary Composite Endpoint for the Four Factorial Groups.
Adapted with permission from
American Heart Journal:
“Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J [Internet]. 2014 Apr [cited 2014 Jun 5]; Available from: http://dx.doi.org/10.1016/j.ahj.2014.02.012

Julio G. Peguero, et al. Trends Cardiovasc Med. ;24(6):232-240.
16.

Figure 2. Improvement in systemic iron burden with combined chelation therapy. From: Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia.

The magnitude of change in LIC (a) and ferritin (b) over 12 months is shown as decrease or increase in the measured value compared with baseline for each subject. The inset graph shows group medians and range. P values evaluate the significance of improvement in LIC at 6 months and 12 months.

Ashutosh Lal, et al. Blood Cells Mol Dis. ;50(2):99-104.
17.
Figure 5

Figure 5. From: Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients.

5-year Kaplan-Meier Event Rate Estimates for the Primary Composite Endpoint in Diabetic Patients. Active-active vs. Placebo-placebo
Adapted with permission from
American Heart Journal:
“Lamas GA., Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J [Internet]. Elsevier B.V.; 2014 Apr [cited 2014 Jun 5]; Available from: http://dx.doi.org/10.1016/j.ahj.2014.02.012

Julio G. Peguero, et al. Trends Cardiovasc Med. ;24(6):232-240.
18.
Figure 3

Figure 3. From: Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.

The figure summarizes the Australian practice guidelines in treating transfusional iron overload in TDT.
Notes: (A) Describes the different choices of iron chelators depending on age. (B) Summarizes the recommendations for iron chelation therapy based on cardiac disease status and cardiac T2*.
Abbreviations: TDT, transfusion-dependent thalassemia; DFX, deferasirox; DFO, deferoxamine; h, hour; DFP, deferiprone; SC, subcutaneously.

Antoine N Saliba, et al. J Blood Med. 2015;6:197-209.
19.
Figure 4

Figure 4. From: Targeted chelation therapy with EDTA-loaded albumin nanoparticles regresses arterial calcification without causing systemic side effects.

Evaluation of aortic calcification for both systemic EDTA chelation therapy and targeted EDTA chelation therapy. A: Aortic calcification evaluated by stereomicroscope before and after whole aorta’s Alizarin red stain for control IgG antibody coated and EDTA loaded NPs (IgG-NPs/EDTA) and elastin antibody coated antibody coated and EDTA loaded NPs (EL-NPs/EDTA) groups (n=5). B: Histological stain by Alizarin red for IgG-NPs/EDTA and EL-NPs/EDTA groups (n=5). C: Ca quantification in aorta by AAS for all five treatment groups (n=5/group). HD EDTA: 50 mg EDTA/kg dose, LD EDTA: 2.5 mg EDTA/Kg dose.* Only EL-NPs/EDTA was statistically lower in value than any other group.

Yang Lei, et al. J Control Release. ;0:79-86.
20.
Figure 1

Figure 1. From: Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome.

Hemoglobin and serum ferritin levels for a patient with MDS receiving iron chelation therapy. The solid black arrow represents the date at which chelation was initiated and the dashed arrow represents the date of his last red blood cell transfusion. The grey bar indicates the period during which transfusion requirement was 3 red blood cell units every 4 weeks.

Maha A. Badawi, et al. Adv Hematol. 2010;2010:164045.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk